| 2024 |
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients |
Articolo in rivista |
Go to |
| 2024 |
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma |
Articolo in rivista |
Go to |
| 2024 |
Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients |
Articolo in rivista |
Go to |
| 2024 |
AURKA targeting: a NEAT approach to halt myeloma |
Articolo in rivista |
Go to |
| 2023 |
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma |
Articolo in rivista |
Go to |
| 2023 |
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma |
Articolo in rivista |
Go to |
| 2023 |
Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma |
Articolo in rivista |
Go to |
| 2023 |
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials |
Articolo in rivista |
Go to |
| 2023 |
Immune Cells, Cytokines, and Gut Microbiota Landscape Along Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Evolution |
Poster pubblicato in rivista |
Go to |
| 2023 |
Unveiling Novel Therapeutic Targets for CAR Therapy in Multiple Myeloma through Single-Cell RNA Sequencing |
Abstract in rivista |
Go to |
| 2023 |
Multiple Myeloma in 2023 Ways: From Trials to Real Life |
Articolo in rivista |
Go to |
| 2023 |
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance |
Articolo in rivista |
Go to |
| 2023 |
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome |
Articolo in rivista |
Go to |
| 2023 |
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again |
Review essay (rassegna critica) |
Go to |
| 2022 |
A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma |
Articolo in rivista |
Go to |
| 2022 |
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma |
Articolo in rivista |
Go to |
| 2022 |
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials |
Articolo in rivista |
Go to |
| 2022 |
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials |
Articolo in rivista |
Go to |
| 2022 |
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach |
Articolo in rivista |
Go to |
| 2022 |
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma |
Articolo in rivista |
Go to |
| 2022 |
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection |
Articolo in rivista |
Go to |
| 2022 |
Network meta-analysis of randomized trials in multiple myeloma efficacy and safety in frontline therapy for patients not eligible for transplant |
Articolo in rivista |
Go to |
| 2022 |
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials |
Articolo in rivista |
Go to |
| 2021 |
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia |
Articolo in rivista |
Go to |
| 2021 |
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response |
Review essay (rassegna critica) |
Go to |
| 2021 |
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients |
Articolo in rivista |
Go to |
| 2021 |
Mechanisms of immune evasion in multiple myeloma: Open questions and therapeutic opportunities |
Articolo in rivista |
Go to |
| 2021 |
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients |
Articolo in rivista |
Go to |
| 2021 |
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study |
Lettera |
Go to |
| 2021 |
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation |
Articolo in rivista |
Go to |
| 2021 |
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report |
Articolo in rivista |
Go to |
| 2021 |
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility |
Articolo in rivista |
Go to |
| 2021 |
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy |
Recensione in rivista |
Go to |
| 2021 |
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens |
Articolo in rivista |
Go to |
| 2021 |
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies |
Articolo in rivista |
Go to |
| 2021 |
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials |
Lettera |
Go to |
| 2021 |
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study |
Lettera |
Go to |
| 2021 |
Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing |
Articolo in rivista |
Go to |
| 2021 |
Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report |
Articolo in rivista |
Go to |
| 2021 |
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma |
Articolo in rivista |
Go to |
| 2021 |
COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm |
Articolo in rivista |
Go to |
| 2021 |
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology |
Articolo in rivista |
Go to |
| 2020 |
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma |
Articolo in rivista |
Go to |
| 2020 |
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma |
Articolo in rivista |
Go to |
| 2020 |
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab |
Articolo in rivista |
Go to |
| 2020 |
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma |
Articolo in rivista |
Go to |
| 2020 |
Immunologic characterization of COVID-19 patients with hematological cancer |
Lettera |
Go to |
| 2020 |
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths |
Articolo in rivista |
Go to |
| 2020 |
Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report |
Articolo in rivista |
Go to |
| 2020 |
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination |
Articolo in rivista |
Go to |
| 2019 |
Could PD-1/PDL1 immune checkpoints be linked to HLA signature? |
Articolo in rivista |
Go to |
| 2019 |
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up |
Articolo in rivista |
Go to |
| 2019 |
Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma |
Articolo in rivista |
Go to |
| 2019 |
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab |
Articolo in rivista |
Go to |
| 2019 |
miR-22 suppresses DNA ligase III addiction in multiple myeloma |
Articolo in rivista |
Go to |
| 2019 |
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma |
Articolo in rivista |
Go to |
| 2018 |
MIR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells |
Articolo in rivista |
Go to |
| 2018 |
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells |
Articolo in rivista |
Go to |
| 2018 |
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine |
Articolo in rivista |
Go to |
| 2018 |
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis |
Articolo in rivista |
Go to |
| 2018 |
Mouse models of multiple myeloma: Technologic platforms and perspectives |
Articolo in rivista |
Go to |
| 2017 |
Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev) |
Articolo in rivista |
Go to |
| 2017 |
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients |
Articolo in rivista |
Go to |
| 2017 |
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in relapsed/refractory patients |
Articolo in rivista |
Go to |
| 2017 |
Immunomodulatory activity of microRNAs: Potential implications for multiple myeloma treatment |
Articolo in rivista |
Go to |
| 2016 |
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients |
Articolo in rivista |
Go to |
| 2016 |
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells |
Articolo in rivista |
Go to |
| 2016 |
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival |
Articolo in rivista |
Go to |
| 2016 |
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation |
Articolo in rivista |
Go to |
| 2016 |
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients |
Articolo in rivista |
Go to |
| 2016 |
OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes |
Articolo in rivista |
Go to |
| 2016 |
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients |
Articolo in rivista |
Go to |
| 2016 |
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis |
Articolo in rivista |
Go to |
| 2016 |
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse |
Articolo in rivista |
Go to |
| 2016 |
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer |
Articolo in rivista |
Go to |
| 2016 |
The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response |
Articolo in rivista |
Go to |
| 2016 |
Immunotherapy of colorectal cancer: New perspectives after a long path |
Articolo in rivista |
Go to |
| 2016 |
Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates |
Articolo in rivista |
Go to |
| 2015 |
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? |
Articolo in rivista |
Go to |
| 2015 |
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies |
Articolo in rivista |
Go to |
| 2015 |
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo |
Articolo in rivista |
Go to |
| 2015 |
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients |
Articolo in rivista |
Go to |
| 2015 |
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts |
Articolo in rivista |
Go to |
| 2014 |
A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells |
Articolo in rivista |
Go to |
| 2014 |
Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials |
Articolo in rivista |
Go to |
| 2014 |
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial |
Articolo in rivista |
Go to |
| 2014 |
Myeloid derived suppressor cells in multiple myeloma: Preclinical research and translational opportunities |
Articolo in rivista |
Go to |
| 2013 |
Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice |
Articolo in rivista |
Go to |
| 2013 |
Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients |
Articolo in rivista |
Go to |
| 2013 |
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: Do we still need it? |
Articolo in rivista |
Go to |
| 2013 |
Immunologic microenvironment and personalized treatment in multiple myeloma |
Articolo in rivista |
Go to |
| 2013 |
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials |
Articolo in rivista |
Go to |
| 2013 |
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease |
Articolo in rivista |
Go to |
| 2012 |
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma |
Articolo in rivista |
Go to |
| 2012 |
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro |
Articolo in rivista |
Go to |
| 2012 |
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients |
Articolo in rivista |
Go to |
| 2012 |
Tumor infiltration by chemokine receptor 7 (CCR7)+ T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer |
Articolo in rivista |
Go to |
| 2011 |
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients |
Articolo in rivista |
Go to |
